

CITATION REPORT

List of articles citing

Riociguat: a novel new drug for treatment of pulmonary hypertension

DOI: 10.1002/phar.1592

Pharmacotherapy, 2015, 35, 502-19.

Source: <https://exaly.com/paper-pdf/60642322/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
27	Treatment of patients with chronic thrombo embolic pulmonary hypertension: focus on riociguat. <i>Therapeutics and Clinical Risk Management</i> , 2016 , 12, 957-64	2.9	5
26	Inhaled Iloprost for Chronic Thromboembolic Pulmonary Hypertension (CTEPH) During Pregnancy: A Case Report. <i>Pharmacotherapy</i> , 2016 , 36, e142-7	5.8	4
25	Potential new drug treatments for congestive heart failure. <i>Expert Opinion on Investigational Drugs</i> , 2016 , 25, 811-26	5.9	13
24	Pulmonary arterial hypertension: Basic knowledge for clinicians. <i>Archives of Cardiovascular Diseases</i> , 2016 , 109, 550-561	2.7	25
23	Nitroglycerin? Yes or No? That Is the Question! Risk of Administering Sublingual Nitroglycerin When the Patient Is Using Phosphodiesterase-5 Inhibitors. <i>Journal of Emergency Nursing</i> , 2016 , 42, 434-7	1.3	1
22	A Contemporary Approach to Pulmonary Arterial Hypertension. <i>Current Atherosclerosis Reports</i> , 2016 , 18, 58	6	1
21	Current progress in therapeutic agents for pulmonary arterial hypertension: new insights into their mechanisms of action from endothelin system. <i>Folia Pharmacologica Japonica</i> , 2016 , 148, 231-238	0	
20	Advances in treatment of pulmonary arterial hypertension: patent review. <i>Expert Opinion on Therapeutic Patents</i> , 2017 , 27, 907-918	6.8	9
19	Trans-4-methoxy-βitrostyrene relaxes rat thoracic aorta through a sGC-dependent pathway. <i>European Journal of Pharmacology</i> , 2017 , 807, 182-189	5.3	8
18	Identification and characterization of antibacterial compound(s) of cockroaches (<i>Periplaneta americana</i>). <i>Applied Microbiology and Biotechnology</i> , 2017 , 101, 253-286	5.7	40
17	A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018 , 123, 103-113	3.1	15
16	The nitric oxide-guanylate cyclase pathway and glaucoma. <i>Nitric Oxide - Biology and Chemistry</i> , 2018 , 77, 75-87	5	29
15	Titration of pulmonary arterial hypertension therapeutics: Experience-based recommendations. <i>Respiratory Medicine</i> , 2018 , 143, 139-146	4.6	3
14	Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential. <i>Nitric Oxide - Biology and Chemistry</i> , 2018 , 78, 72-80	5	49
13	Hypercoagulability in Pulmonary Hypertension. <i>Clinics in Chest Medicine</i> , 2018 , 39, 595-603	5.3	7
12	Development of a CE-MS method for the study of riociguat and metabolite M1 in pharmaceutical analysis. <i>Electrophoresis</i> , 2019 , 40, 2936-2945	3.6	1
11	cGMP modulation therapeutics for sickle cell disease. <i>Experimental Biology and Medicine</i> , 2019 , 244, 132-146	3.46	14

10 Pulmonary Arterial Hypertension in HIV. **2019**, 159-170

9 A Randomized, Placebo-Controlled, Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Soluble Guanylate Cyclase Stimulator Praliguat in Healthy Subjects. *Clinical Pharmacology in Drug Development*, **2019**, 8, 564-575 2.3 14

8 Discovery of Novel Pyrazolo[3,4-] Pyridine Derivatives with Dual Activities of Vascular Remodeling Inhibition and Vasodilation for the Treatment of Pulmonary Arterial Hypertension. *Journal of Medicinal Chemistry*, **2020**, 63, 11215-11234 8.3 11

7 Advances in Sickle Cell Disease Treatments. *Current Medicinal Chemistry*, **2021**, 28, 2008-2032 4.3 3

6 A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects. *Drug Design, Development and Therapy*, **2021**, 15, 2947-2959 4.4 0

5 Impact of pregnancy in patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: case series and literature review.. *Lupus Science and Medicine*, **2022**, 9, 4.6 0

4 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. 2200879 18

3 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. 58

2 Drug Interactions Associated With Therapies for Pulmonary Arterial Hypertension. 875512252211140 0

1 Long-term outcomes of combined pulmonary endarterectomy and additional balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. 1